| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Palbociclib D8 targets the same enzymes as its unlabeled parent drug. Palbociclib is a selective and orally active inhibitor of CDK4 and CDK6 with IC50 values of 11 and 16 nM, respectively. By inhibiting these kinases, it blocks the phosphorylation of the retinoblastoma protein (Rb), leading to cell cycle arrest in the G1 phase.
|
|---|---|
| ln Vitro |
Palbociclib D8 is primarily used as an analytical internal standard rather than for its pharmacological activity. Palbociclib is a CDK4/6 inhibitor used in the treatment of hormone receptor-positive breast cancer. The compound is used in LC-MS/MS methods for the quantification of Palbociclib in biological matrices. The deuterium labeling provides a mass shift for accurate quantification.
|
| ln Vivo |
Palbociclib D8 is used in pharmacokinetic studies as an internal standard for the quantification of Palbociclib. Palbociclib is a CDK4/6 inhibitor approved for the treatment of hormone receptor-positive breast cancer. The deuterium-labeled compound can be co-administered with unlabeled Palbociclib to study absorption, distribution, metabolism, and excretion.
|
| Enzyme Assay |
In vitro assays for Palbociclib D8 are typically performed as part of analytical method validation. The compound is used as an internal standard in LC-MS/MS assays for the quantification of Palbociclib. It is dissolved in an appropriate solvent and spiked into biological matrices at known concentrations. Calibration curves are generated by plotting the peak area ratio of Palbociclib to Palbociclib D8 against the concentration of Palbociclib.
|
| Cell Assay |
For in vitro cell-based assays, Palbociclib D8 can be used in studies investigating Palbociclib's cellular effects, though its primary use is as an analytical internal standard. Cancer cell lines are cultured and treated with the compound. CDK4/6 inhibition is confirmed by measuring the phosphorylation of Rb via Western blot. Cell viability is assessed by MTT or CellTiter-Glo assays.
|
| Animal Protocol |
In vivo animal studies with Palbociclib D8 are primarily pharmacokinetic. The compound is administered orally to rodents, and blood samples are collected at predetermined time points. Plasma concentrations of both labeled and unlabeled Palbociclib are analyzed by LC-MS/MS using Palbociclib D8 as the internal standard. Pharmacodynamic effects can be evaluated in xenograft models.
|
| ADME/Pharmacokinetics |
Palbociclib D8 (CAS: 1628752-83-9) has a molecular weight of 455.59 g/mol and a molecular formula of C24H21D8N7O2. Appearance: solid powder. Purity: ≥99% deuterated forms (d1-d8). Storage: -20°C. The compound is a deuterium-labeled internal standard for Palbociclib.
|
| Toxicity/Toxicokinetics |
Palbociclib D8 is used in very small quantities as an analytical internal standard and does not pose significant toxicity risks under normal handling. As a deuterium-labeled analog of an approved drug, it is expected to have a similar pharmacological profile, but toxicology studies are typically not performed on the labeled compound. Palbociclib is generally well-tolerated.
|
| References | |
| Additional Infomation |
Palbociclib D8 (PD-0332991 D8) is a deuterium-labeled form of Palbociclib, a selective and orally active CDK4/6 inhibitor used for hormone receptor-positive breast cancer. It has the CAS number 1628752-83-9 and a molecular weight of 455.59 g/mol. It is not intended for therapeutic use and is for research and analytical use only.
|
| Molecular Formula |
C24H21D8N7O2
|
|---|---|
| Molecular Weight |
455.582
|
| Exact Mass |
455.288
|
| CAS # |
1628752-83-9
|
| Related CAS # |
Palbociclib;571190-30-2;Palbociclib monohydrochloride;827022-32-2;Palbociclib hydrochloride;571189-11-2;Palbociclib dihydrochloride
|
| PubChem CID |
76974685
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
1.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
775
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(NC2N=CC(N3C([2H])([2H])C([2H])([2H])NC([2H])([2H])C3([2H])[2H])=CC=2)N=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=1
|
| InChi Key |
AHJRHEGDXFFMBM-PMCMNDOISA-N
|
| InChi Code |
InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)/i9D2,10D2,11D2,12D2
|
| Chemical Name |
6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(2,2,3,3,5,5,6,6-octadeuteriopiperazin-1-yl)pyridin-2-yl]amino]pyrido[2,3-d]pyrimidin-7-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~8.33 mg/mL (~18.28 mM)
DMSO : ~1 mg/mL (~2.20 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1950 mL | 10.9750 mL | 21.9500 mL | |
| 5 mM | 0.4390 mL | 2.1950 mL | 4.3900 mL | |
| 10 mM | 0.2195 mL | 1.0975 mL | 2.1950 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
